Walter S. Woltosz Sells 20,000 Shares of Simulations Plus, Inc. (NASDAQ:SLP) Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the transaction, the director now owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Simulations Plus Price Performance

Shares of SLP stock opened at $36.19 on Thursday. The stock’s fifty day moving average price is $30.56 and its 200 day moving average price is $32.42. Simulations Plus, Inc. has a 1-year low of $24.00 and a 1-year high of $51.22. The company has a market cap of $727.13 million, a price-to-earnings ratio of 90.48 and a beta of 0.83.

Institutional Investors Weigh In On Simulations Plus

Large investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its position in shares of Simulations Plus by 7.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock valued at $311,000 after purchasing an additional 456 shares during the last quarter. Azzad Asset Management Inc. ADV increased its stake in Simulations Plus by 68.7% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 13,505 shares of the technology company’s stock valued at $432,000 after purchasing an additional 5,498 shares in the last quarter. InTrack Investment Management Inc raised its holdings in shares of Simulations Plus by 5.9% in the third quarter. InTrack Investment Management Inc now owns 33,543 shares of the technology company’s stock worth $1,074,000 after buying an additional 1,878 shares during the last quarter. Kings Path Partners LLC lifted its stake in shares of Simulations Plus by 19.2% during the third quarter. Kings Path Partners LLC now owns 22,560 shares of the technology company’s stock worth $722,000 after buying an additional 3,633 shares during the period. Finally, nVerses Capital LLC grew its holdings in shares of Simulations Plus by 1,100.0% during the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock valued at $38,000 after buying an additional 1,100 shares during the last quarter. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Analyst Upgrades and Downgrades

SLP has been the topic of a number of recent research reports. Stephens initiated coverage on shares of Simulations Plus in a research note on Friday, November 15th. They set an “overweight” rating and a $39.00 price objective on the stock. BTIG Research dropped their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. StockNews.com lowered Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. Finally, KeyCorp boosted their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $49.40.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.